Previous 10 | Next 10 |
BOSTON, May 27, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a virtual fireside chat at the Jefferies 2020 Healthcare Conference on Wednesday, June 3,...
Image source: The Motley Fool. Ziopharm Oncology Inc (NASDAQ: ZIOP) Q1 2020 Earnings Call May 7, 2020 , 4:30 p.m. ET Operator Continue reading
BOSTON, May 08, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the BofA Securities 2020 Health Care Conference on Thursday, May 14, 2020,...
ZIOPHARM Oncology, Inc. (ZIOP) Q1 2020 Earnings Conference Call May 7, 2020 4:30 PM ET Company Participants Chris Taylor - Vice President, Investor Relations and Corporate Communications Laurence Cooper - Chief Executive Officer Satyavrat Shukla - Chief Financial Officer David ...
The following slide deck was published by ZIOPHARM Oncology, Inc. in conjunction with their 2020 Q1 earnings Read more ...
– Regulatory discussions with FDA advance Ziopharm TCR-T IND process – – Enrollment on track in Controlled IL-12 phase 2 clinical trial with Regeneron’s Libtayo ® ; Controlled IL-12 clinical data update at ASCO 2020 – – Work rest...
BOSTON, April 30, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that it will be presenting data from its Controlled IL-12 program, or Ad-RTS-hIL-12 plus veledimex (Ad+V), both as monotherapy and in combination with a PD-1 inhibitor (nivolumab) for the tr...
BOSTON, April 27, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast on Thursday, May 7, at 4:30 pm EDT to provide a corporate update and discuss financial results for the first quarter ended March 31, 2020....
Ziopharm Oncology ( ZIOP ) has been under major pressure after their recent follow-on-offering as well as the collapse in the overall market, explains biotech expert John McCamant , editor of The Medical Technology Stock Letter . Many biotech stocks have been under relentle...
Can These Penny Stocks Keep Heading Higher? Unless you’ve lived under a rock for the last few months, coronavirus is one of the top headline topics of the year. In fact, some of the highest traffic we’ve seen has come over the last month with a major focus on coronavirus penny s...
News, Short Squeeze, Breakout and More Instantly...
ZIOPHARM Oncology Inc Company Name:
ZIOP Stock Symbol:
NASDAQ Market:
ZIOPHARM Oncology Inc Website:
TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patients hunTR® discovered new HLA class I and class II restricted TCRs that recognize d...
TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patients Company to wind down TCR-T Library Phase 1/2 trial and concurrently explore potent...
HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that the Compan...